Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus vitamin K antagonist for patients with nonvalvular atrial fibrillation undergoing cardioversion
2011-002234-39Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Bayer. Started Jul 2012; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2011-002234-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002234-39.